<DOC>
	<DOCNO>NCT02040142</DOCNO>
	<brief_summary>This clinical study investigate new treatment surgery combine intraperitoneal mitomycin-C patient gastrointestinal cancer spread peritoneal ( abdominal cavity ) surface . Mitomycin-C used procedure approve U.S. Food Drug Administration ( FDA ) many different cancer include gastrointestinal cancer . Giving mitomycin C via intraperitoneal route FDA approve investigation therapy . Cytoreductive surgery plus intraperitoneal chemotherapy offer standard care outside clinical trial . However , since unproven potentially effective toxic approach , investigator perform procedure IRB approve clinical trial order well evaluate risk benefit approach . A standardized , evidence-based approach currently lack patient peritoneal surface malignancy gastrointestinal origin . A clinical trial surgical quality assurance modern hyperthermic intraperitoneal chemotherapy incorporate critical assessment disease burden , determinant complete cytoreduction , treatment-related toxicity , quality life survival imperative . Theoretically , cytoreductive surgery perform treat macroscopic disease , hyperthermic intraperitoneal chemotherapy use treat microscopic residual disease objective remove disease completely single procedure .</brief_summary>
	<brief_title>Single Arm Study Treating Patients Peritoneal Surface Malignancy ( Colorectal , Appendical , Pseudomyxoma , Gastric ) With Cytoreductive Surgery Hyperthermic Intraperitoneal Mitomycin-C</brief_title>
	<detailed_description>Patients peritoneal surface malignancy gastrointestinal ( GI ) cancers almost uniformly succumb advance locoregional disease form intractable ascites , malignant visceral obstruction cancer cachexia . The natural history peritoneal carcinomatosis GI malignancies inexorably lethal median overall survival approximately 5 month 7 , patient disease confine peritoneum remain increase risk synchronous occult hematogenous metastasis . While systemic therapy improve outcome patient hematogenous disease spread , improvement need control peritoneal surface malignancy , know relatively resistant systemic agent owe principally presence peritoneal-plasma partition . Moreover , result surgical resection alone peritoneal dissemination GI cancer disappoint give difficulty clear surgically microscopic disease focus . The infusion chemotherapy peritoneal cavity provide distinct pharmacokinetic advantage . The addition hyperthermia potentiates effect intra-peritoneal chemotherapy anti-tumor synergism , without systemic drug absorption . Mitomycin- C cytotoxic agent choice purpose , one study extensively hyperthermic intra-peritoneal chemotherapy patient peritoneal carcinomatosis gastrointestinal origin . Mitomycin- C also show demonstrate consistent pharmacokinetics , favorable toxicity profile , hyperthermia-facilitated tumor cytotoxicity , enhance condition tumor hypoxia ; furthermore , Mitomycin- C contribute improve outcome optimal cytoreduction . Hence , delivery intra-peritoneal heat chemotherapy advantage dose-dense regional delivery cytotoxic agent relatively little systemic toxicity . Current clinical experience suggest add cytoreductive surgery hyperthermic intra-peritoneal chemotherapy modern systemic chemotherapy regimen may significantly improve oncological outcome . The Montefiore-Einstein Center Cancer Care on-going cooperative Cancer Bio-specimen Repository correlative/translational research program identify prognostic factor patient malignant tumor , well factor predictive response toxicity treatment . To support important scientific work , tissue block submission [ primary tumor peritoneal surface malignancy ] along serum specimen mandatory patient provide informed consent bio-specimen submission complete tissue microarrays ( TMA ) may study . These inquiry establish molecular profile biomarkers prognostic predictive value patient gastrointestinal carcinomatosis undergo treatment context trial . The primary endpoint analysis evaluate technical parameter include completeness cytoreduction , achievement hyperthermia , morbidity mortality patient peritoneal carcinomatosis undergo CRS HIPEC Mitomycin- C. Patients satisfy inclusion criterion take operate room exploration cytoreductive surgery . We record completeness cytoreduction ( CC 0 - CC 3 ) describe . Complete cytoreduction define CC 0 CC 1 . Ability achieve adequate hyperthermia define target intraperitoneal temperature 41-43ยบ C. Adverse event assess enrollment follow study treatment . The severity adverse event evaluate use NCI-CTCAE version 4 . Adverse event assess possibly , probably , definitely related study treatment follow AE resolve subject clinically stable . Other safety data include physical examination , vital sign , hematology , clinical chemistry , urinalysis collect time informed consent sign subject discontinuation 12 month initial study treatment , whichever occur first . For every multi-modality ( CRS-HIPEC ) case , follow require context clinical trial : 1 . Patient eligibility trial determine cross-sectional imaging review ; 2 . Pre-operative Peritoneal Cancer Index ( PCI ) score determine CT and/or laparoscopy ; 3 . Cytoreductive surgery undertaken involve six principal peritonectomy procedure , base volume distribution peritoneal surface disease , surgeon 's discretion , effort achieve complete resection grossly apparent peritoneal surface disease . Intraoperative PCI determine begin cytoreductive surgery ; 4 . Heated intra-operative intra-peritoneal chemotherapy deliver ; 5 . At completion perfusion , abdomen re-explored , residual fluid aspirate reconstruction complete already complete prior HIPEC ; 6 . Post resection PCI determine completeness cytoreduction estimate use CC RR system define section 5.2 ; 7 . Intra-peritoneal tubes drain place incision leave open close usual fashion surgeon 's discretion ; 5.4 Surgical quality assurance control ( QA/QC ) 5.4.1 Surgical QA/QC strategy For every multi-modality ( CRS-HIPEC ) case , follow require context clinical trial : 1 . Patient eligibility trial determine cross-sectional imaging review ; 2 . Pre-operative PCI score determine CT and/or laparoscopy ; 3 . Cytoreductive surgery undertaken involve six principal peritonectomy procedure , base volume distribution peritoneal surface disease , surgeon 's discretion , effort achieve complete resection grossly apparent peritoneal surface disease . Intraoperative PCI determine begin cytoreductive surgery ; 4 . Heated intra-operative intra-peritoneal chemotherapy deliver ; 5 . At completion perfusion , abdomen re-explored , residual fluid aspirate reconstruction complete already complete prior HIPEC ; 6 . Post resection PCI determine completeness cytoreduction estimate use CC RR system define section 5.2 ; 7 . Intra-peritoneal tubes drain place incision leave open close usual fashion surgeon 's discretion ; 5.5 Supportive care All appropriate supportive care side effect toxicity provide physician Montefiore-Einstein Center Cancer Care Montefiore Medical Center . Patients may admit necessary manage issue relate study treatment procedure . 7.1 Definitions adverse event report Adverse event ( AE ) assessment , data collection report do ensure safety patient enrol study . Adverse event secondary cytoreductive surgery utilization intraperitoneal chemotherapy monitor closely , record appropriately report require . The description grade scale find revise NCI Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 utilized AE reporting . All appropriate treatment area access copy CTCAE version 4.0 . A copy CTCAE version 4.0 download Cancer Therapy Evaluation Program ( CTEP ) web site ( http : //ctep.cancer.gov ) . Timely report serious unexpected adverse event conduct throughout trial period . Only commercial agent ( provide IND ) utilize study . The study subject inform indication , nature , alternative , expect outcome , risk benefit procedure therapy provide context study . Clearly , potential , foreseeable risk discomforts participant study . Detailed information adverse event complication , may relate HIPEC operative procedure provide trial , collect course study . The CTEP CTCAE version 4.0 use identify type , grade severity adverse event trial . An adverse event consider Serious Adverse Event ( SAE ) event lead death , result life-threatening illness injury , result permanent impairment body structure body function , require inpatient hospitalization prolongation exist hospitalization , result medical surgical intervention prevent permanent impairment body structure body function . An Unanticipated Adverse Event ( UAE ) consider serious adverse effect health safety life-threatening problem death cause , associate , commercial agent and/or surgical procedure , effect , problem , death identified nature , severity , degree incidence investigational plan unanticipated serious problem associate commercial agent and/or operation relate right , safety , welfare subject participate study . 7.2 Adverse event assessment The severity type grade adverse event identify use NCI CTCAE , Version 4.0 . Attribution/treatment relation adverse event define study doctor Unrelated , Unlikely , Possible , Probable , Definite . An adverse event define unfavorable unintended sign , include abnormal laboratory finding , symptom , disease temporally associate use investigational product , whether related investigational product . This include occurrence new onset aggravate severity frequency baseline condition . Adverse event ( AEs ) assessments begin time signing informed consent continue 30 day follow study treatment . AEs assess possibly , probably , definitely related study treatment must follow AE resolve patient clinically stable . Other safety assessment , include physical examination , vital sign , hematology , clinical chemistry , urinalysis , do subject discontinuation 12 month initial study treatment , whichever occur first . The condition detect diagnostic procedure conduct test efficacy investigational agent consider AE . Symptoms clinically significant laboratory instrumental abnormality pre-existing disease , cancer disease consider AE . However , occurrence new symptom laboratory instrumental abnormality , well worsen pre-existing one , consider AEs . Abnormal result diagnostic procedure , include laboratory test abnormality , consider adverse event result : - Discontinuation study . - Treatment therapeutic intervention . - Further diagnostic evaluation ( exclude repetition procedure confirm abnormality ) . - Associated clinical sign symptom would significant clinical impact , determine Investigator . Any untoward medical event occur time sign informed consent time immediately prior first study treatment procedure report `` pre-treatment event '' Medical History case report form ( CRF ) . All adverse event occur follow study treatment document AE CRF indication onset , duration , severity ( NCI CTCAEs ) , presume relationship study procedure /medication ( relate , unlikely , possibly , probably , definitely ) , remedial action take , outcome . Surgical complication define secondary event deviate ideal course convalescence occur following operation , result change management ( diagnostic therapeutic intervention ) delay complete recovery and/or adjuvant therapy , chronic disability . Surgical complication score accord five-tier surgical morbidity mortality scale ( accord intensity therapy require treatment defined complication ) : Grade Intensity Treatment 1 . Oral medication ( e.g . oral antibiotic surgical site infection bedside care ) 2 . Intravenous medication nutrition ( e.g . antiarrhythmic therapy supraventricular tachycardia ) 3 . Endoscopy , interventional radiology reoperation ( e.g . operative drainage abscess ) 4 . Chronic disability major organ resection ( e.g . reduction performance status follow post respiratory failure ) 5 . Death 7.3 Expedited Reporting Adverse Events Expedited adverse event reporting patient receive commercial agent require : - All Grade 4 5 unexpected adverse event possibly , probably definitely related therapy . - All Grade 5 adverse event , regardless attribution , occur within 30 day end therapy Expedited adverse event report NOT require following : โข Adverse event relate surgery - Adverse event relate radiation - Adverse event occur follow first cancer recurrence second primary cancer development 7.4 Routine Reporting Adverse Events All Grade 3-5 AEs must record appropriate data form . Expedited report addition , supplant , report AEs part data submission requirement study . Adverse event categorize body system ( cardiovascular-related , renal-related , etc . ) report Montefiore institutional review board ( IRB ) require IRB . Any serious event , include death cause occur 30 day follow study treatment , whether related investigational drug , must report PI immediately ( within 24 hour ) via telephone , fax , e-mail . If initially report via telephone e-mail , must followed-up write faxed report submit within 24 hour initial report . Initial Reports Within 24 hour investigator 's knowledge serious adverse event : โข Complete Serious Adverse Event Report Form ( SAER ) , sign , fax PI . - Place initial version SAER subject 's file . Follow-Up Reports New information receive spontaneously request Medical Monitor Safety Surveillance . Within 48 hour receipt new information : โข Complete new SAER new information . Sign fax form PI . โข Fax copy support document ( e.g. , hospital discharge summary , lab test result normal range , autopsy biopsy report ) PI . - Place follow-up version SAE support documentation subject 's file . Final Report Within 48 hour receipt final information : โข Determine information available update may consider final . - Complete new SAER form new final information . Sign fax form PI . As , send copy additional support information . - Place version final SAER subject 's file . It imperative IRB inform within 24 hour serious adverse experience report FDA meet within require time frame ( 7 15 calendar day ) . Because need report health authority serious adverse experience timely manner , vitally important Investigator report immediately adverse experience , would consider serious , even Investigator consider adverse experience clinically significant drug-related . Should Investigator become aware SAE ( regardless relationship study treatment ) occur subject study , SAE must report accordance procedure specify protocol . If subject withdrawn le 30 day study treatment , SAEs occur within 30 day study treatment must report accordance procedure specify protocol . All serious adverse event assess possibly , probably , definitely related study treatment follow either : adverse event resolve , adverse event stabilizes , adverse event return baseline value ( baseline value available ) , show adverse event attributable study treatment study conduct . 8.1 Bio-specimen collection Collection submission primary tumor ( case synchronous disease ) , peritoneal surface malignancy , peritoneal cytology perfusate , serum sample require patient consent participation correlative science study . Frozen tumor tissue tumor tissue ( primary cancer peritoneal surface ) block , peritoneal fluid cytology , peritoneal perfusate serum sample use correlative science study describe . Patients also may consent storage unused sample future research . Analysis result report study subject impact study subject treat follow protocol . The tumor sample , peritoneal fluid washing perfusate sample process Cancer Bio-specimen Repository ( CBSR ) accordance routine tissue banking policy include : โข Safeguards address medical-legal concern submit pathologist โข Quality control storage section tissue tissue block โข Quality assurance stored/sectioned tissue tissue block โข Scientific review process utilization human biological specimen CBSR approve protocol . The CBSR core laboratory affiliate Einstein-Montefiore Institute Clinical Translational Research ( ICTR ) locate 9.0 ETHICAL CONSIDERATIONS 9.1 IRB review The study conduct Montefiore Medical Center , compliance Title 21 Code Federal Regulations ( CFR ) , Part 50 ( Protection Human Subjects ) , Part 56 ( Institutional Review Board ) well principles Declaration Helsinki amendment . The Montefiore Institutional Review Board ( IRB ) review protocol informed consent . The study initiate without IRB approval . All subject require give write informed consent prior participation study . This study perform accordance Good Clinical Practices ( GCP ) qualify Investigators . The study specifically incorporate follow feature : - Single arm study design - Prospectively state objective analytical plan - Accepted , pre-specified outcome measure safety efficacy - Compliance Good Clinical Practices ( GCP ) , assessment via regular monitoring . Quality assurance procedure perform assure safety efficacy data adequate well document . In order maintain patient confidentiality , case report form , study report communication relate study identify subject initial assign subject number ; subject identify name . In accordance local , national federal regulation , Investigator allow personnel data monitoring committee access pertinent medical record order verify data gather case report form . Regulatory agency US Food Drug Administration ( FDA ) may also request access study record , include source documentation inspection . Clinical information release without write permission subject outline subject consent form . Researchers ensure confidentiality information gather study use follow method : - Paper base record keep secure location accessible personnel involve study . - All study data keep lock file cabinet password protect file . - Computer base file make available personnel involve study use access privilege password . - Prior access study-related information , personnel require sign statement agree protect security confidentiality identifiable health information . - Whenever feasible , identifier remove study-related information . 10 . STATISTICAL CONSIDERATION 10.1 Sample size The target number patient propose protocol base primary objective , assess completeness cytoreduction . The achievement hyperthermia well postoperative morbidity mortality important factor interim analysis also . The latent goal utilize estimate generate future research hypotheses protocol development well benchmark data publish data . Sample size calculation base primary objective . Our target sample size 50 patient unless undue toxicity encounter accrual terminate interim analysis . A sample size n=50 , would produce two-sided 95 % confidence interval maximum width 0.289 proportion 0.5 0.267 proportion 0.70 . Calculations base exact binomial distribution . In large multi-institutional study , 75 % patient classify Complete continuous remission 0 ( CCR ) 17 % CCR-1 1 . 10.2 Statistical Data Analysis Data enter excel spreadsheet analyze SAS v9.2 . Data analysis precede quality control data include check accuracy , completeness internal validity . Rates completeness cytoreduction , achievement hyperthermia postoperative morbidity mortality compute report 95 % confidence interval . Descriptive data analysis conduct adverse event overall patient characteristic describe . Bivariate analysis conduct examine factor associate complete cytoreduction achievement hyperthermia . Categorical variable analyze use Fisher 's exact test . Continuous variable whose distribution meet normality assumption analyze t-test . Variables whose distribution approximate normality analyze use Wilcoxon rank sum test . For secondary endpoint evaluate time progression , progression-free survival overall survival use Kaplan-Meier method . Progression-free survival calculate time surgery date recurrence censor time patient last see . Overall survival calculate time surgery time death censor time patient last see . Log-rank test use compare survival patient achieve complete cytoreduction . We compute 95 % confidence interval use Greenwood 's formula . QOL data collect use Functional Assessment Cancer Treatment ( FACT-C ) instrument . The feasibility collect QOL data assess rate miss data compute . Reasons miss data characterize extent possible . In addition , QOL data describe use mean , standard deviation , median , inter-quartiles range well graphically . For exploratory analysis QOL data time examine use hierarchical linear model . Epigenetic genomic data examine exploratory manner goal inform formulation new research hypothesis . 10.2.1 Interim Analysis Decision Rules Interim analysis perform first enrol 20 case assess safety propose treatment . Stopping rule base 30-day postoperative mortality . The overall mortality rate report Glehen et al large retrospective series patient Peritoneal Carcinomatosis ( PC ) treat Cytoreductive Surgery combination HIPEC 4.1 % . Based Glehen 's data , upper limit 95 % confidence interval around 4.1 % mortality rate 5.3 % . While anticipated mortality rate 5 % - comparable report Glehen - give variability origin PC , give variability report mortality rate report Koppe eta ! 58 give patient undergo approach advance disease often progress therapies- consider 30-day mortality rate ( therapy ) great I 0 % unacceptable since rate high one would expect large retrospective series available . The 30-day mortality evaluate first 20 patient enrol . If 2 patient ( I 0 % ) suffer mortality within 30 day attributable therapy underlie disease unrelated therapy , continue 50 patient . If 3 patient suffer mortality within 30 day therapy directly attributable therapy , suspend accrual investigate cause high mortality . After root cause operative mortality determine , study team confer IRB make determination whether accrual resume . 10.3 Patient Accrual : Based experience Montefiore-Einstein Center Cancer Care base number patient see first half year , expect screen 30 patient yearly . We estimate 2/3 patient meet inclusion criterion study . We expect high rate participation protocol estimate take u 2-3 year recruit propose sample 50 patient . We follow-up patient evidence progression total study time 5 year . 10.4 Interim Reports Interim report prepare every 12 month . These include : - Monthly patient accrual rate - Descriptive patient 's demographic characteristic - Descriptive clinical data - Frequency severity adverse event 11 . DATA COLLECTION AND REPORTING 11.1 Data collection Complete research record medical record must maintain patient treat protocol schedule unscheduled evaluation . These record include primary documentation ( e.g . laboratory report , X-ray report , scan report , pathology report , physician 's note , etc . ) confirm : - The patient meet eligibility criterion - Signed informed consent obtain prior treatment - Treatment give accord protocol ( dated note dos give , complication , clinical outcome ) . - Toxicity assess accord protocol . - Response assess accord protocol ( X-ray , CT-scan , MRI , lab report , date note clinical assessment , appropriate ) . - MMC Drug Accountability Records keep patient . - The patient use diary document daily adverse event . 11.2 Data Safety Monitoring Plan The PI research personnel meet least monthly review adverse event . Unexpected adverse event and/or serious adverse event report MMC IRB . If trend note /or risk warrant , accrual interrupt /or protocol and/or consent modify accordingly . The MMC IRB review submit adverse event monthly also evaluate trend require follow plan principal investigator whenever trend identify . 11 . 3 Data Reporting All patient must sign informed consent form on-study ( confirmation eligibility ) form fill sign participate Investigator enter study . Patients follow least monthly therapy development toxicity . Toxicity score use CTCAE Version 4.0 toxicity adverse event reporting . All adverse clinical experience , whether observe investigator report patient , must record , detail duration intensity episode , action take respect study treatment , patient 's outcome . The investigator must evaluate adverse experience relationship study treatment seriousness . 11.3.1 Routine Data Reporting : Data capture MMC C3D web base reporting system . A minimum 25 % data source data verify . Grade 1 2 lab toxicity medication use treat adverse event maintain source document capture C3D . Only follow outside lab capture C3D : โข Hemoglobin , WBC , ANC , Platelets , alanine aminotransferase/ aspartate aminotransferase ( ALT/AST ) , total bilirubin , Creatinine { lab associate serious adverse event may capture appropriate } 11.3.2 Expedited Reporting Deaths Study Adverse Events The protocol PI report MMC-IRB : - All death - All grade 3 4 ( CTCAE ) event list consent form possibly , probably definitely relate research - All serious adverse event ( SAEs ) list consent form , possibly , probably definitely relate research . An SAE define untoward medical occurrence : - Resulted death - Was life-threatening - Required prolonged hospitalization - Caused persistent significant disability/incapacity - Resulted congenital anomaly birth defect - Required intervention prevent permanent impairment death - Is important medical event - Suspected positive Pregnancy 11.3.3 Adverse Event Reporting Continuing Review Report Data submit review IRB annually . The MMC-IRB require summary report adverse event occur protocol since previous continue review . The method presentation provide MMC-IRB information necessary clearly identify risk participant make risk : benefit determination . The summary report base follow guidance : - Any unexpected severity and/or unexpected frequency expect event need report interpreted relation risk : benefit study participant narrative . - Grade 1 event require . - Grade 2 unexpected relate research event require . - Grade 3 4 expect unexpected event relate research require . - All Serious Events regardless attribution . - Grade 5 ( ) event include regardless attribution . Based protocol-associated risk participant , MMC-IRB retain authority establish frequent Continuing Review period customary annual review period .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Pseudomyxoma Peritonei</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Age โฅ 18 year Capable provide informed consent . The patient previously receive hyperthermic intraperitoneal chemotherapy must histopathologically cytologically confirm cancer colorectal , appendiceal , peritoneal mesothelioma , pseudomyxoma gastric origin know synchronous metachronous disease dissemination limit peritoneal surface . The patient must document disease limited peritoneal surface , amenable complete cytoreduction indicate : Disease confine peritoneal surface No parenchymal liver metastases No evidence clinical , biochemical radiological biliary obstruction Small volume disease gastrohepatic ligament define &lt; 5cm mass epigastric region crosssectional imaging No clinical radiological evidence hematogenous distant nodal metastasis Eastern Cooperative Oncology Group ( ECOG ) performance status โค 1 Absolute neutrophil count ( ANC ) &gt; 1200/mm3 , white blood cell count ( WBC ) &gt; 4000/mm3 platelet count &gt; 150,000/mm3 An international normalized ratio ( INR ) โค 1.5 ( patient therapeutically anticoagulated unrelated medical condition atrial fibrillation whose antithrombotic treatment withheld operation eligible ) . Adequate hepatic function must meet evidenced total serum bilirubin โค 1.5 mg/dl ( patient total bilirubin &gt; 1.5 mg/dL eligible Gilbert 's syndrome ) ; alkaline phosphatase &lt; 2.5 time upper limit normal ; and/or AST &lt; 1.5 time upper limit normal ( alkaline phosphatase AST exceed upper limit normal Serum renal functional parameter , blood urea nitrogen ( BUN ) creatinine within normal limit Satisfactory cardiopulmonary function ( history severe congestive heart failure severe pulmonary disease , indicate clinically acceptable risk undergo major abdominal cytoreductive surgery ) . Patients meet criterion undergone CRS HIPEC past 18 month beforementioned disease process without evidence recurrence eligible participation study analyze ability achieve complete cytoreduction , morbidity , progression survival . The patient document disease beyond peritoneal surface , prevent achieve complete cytoreduction indicate : Evidence distant hematogenous metastatic disease distant nodal metastasis Evidence parenchymal hepatic metastasis Evidence clinical , biochemical radiological biliary obstruction Evidence gross disease small bowel mesentery characterize distortion , thicken loss mesenteric vascular clarity limit ability obtain complete cytoreduction Significant history medical problem comorbidity would preclude patient undergo major abdominal operation history severe congestive heart failure active ischemic heart disease . Active systemic infection , coagulation disorder , major medical illness preclude major surgery . Childs B C cirrhosis evidence severe portal hypertension history , endoscopy radiologic study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hyperthermic Intraperitoneal Mitomycin c</keyword>
	<keyword>HIPEC</keyword>
	<keyword>Cytoreduction</keyword>
</DOC>